{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T21:06:28Z","timestamp":1724879188082},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T00:00:00Z","timestamp":1685664000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Breast cancer is the most common cancer among Japanese women and often yields a better prognosis than other cancers. However, few studies have been conducted on pain control using opioids in Japan. In this study, we aimed to examine actual opioid use among breast cancer patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Breast cancer patients were defined as female patients with a first breast cancer diagnosis during the observational period in an acute care hospital database (April 2008\u2009\u2212\u2009February 2020). We examined the percentage of patients prescribed opioids, the opioid amount per patient, and the opioid dosage per day around surgery, bone metastasis diagnosis, or death.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Overall, 217,722 breast cancer patients were identified. The percentage of patients prescribed opioids and the average amount of opioids per patient were highest in the month of surgery, 78% and 27 morphine milligram equivalents (MMEs), respectively. The average opioid dosage increased with time after surgery from 19 to 28 MMEs. Around bone metastasis, the percentage of patients prescribed opioids and the average opioid amount per patient peaked one month after the diagnosis, 31% and 371 MMEs, respectively. The average opioid dosage gradually increased from 22 to 35 MMEs in succeeding days after a bone metastasis diagnosis. The percentage of patients prescribed opioids and the average opioid amount per patient increased as the month of death approached.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>We investigated opioid prescription trends around clinical events in breast cancer patients on a large scale in Japan. These results may be useful to control cancer pain among breast cancer patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00520-023-07805-4","type":"journal-article","created":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T09:42:27Z","timestamp":1685698947000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Opioid prescriptions at the point of surgery, bone metastasis, or death among patients with breast cancer in Japanese acute care hospitals: a claims-based, retrospective, longitudinal study"],"prefix":"10.1007","volume":"31","author":[{"given":"Manami","family":"Yoshida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsunori","family":"Miyashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Saeki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhide","family":"Morioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinzo","family":"Hiroi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiko","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,2]]},"reference":[{"key":"7805_CR1","unstructured":"National Cancer Center, Ministry of Health, Labour and Welfare (2019) Cancer information service, National Cancer Registry. https:\/\/ganjoho.jp\/reg_stat\/statistics\/data\/dl\/en.html. Accessed date 14 Nov 2022"},{"key":"7805_CR2","unstructured":"National Cancer Center, Ministry of health, labour and welfare (2021) [Hospital-based Cancer Registry: Report on 10-year survival rate in 2008]. https:\/\/ganjoho.jp\/public\/qa_links\/report\/hosp_c\/hosp_c_reg_surv\/pdf\/hosp_c_reg_surv_10_2008.pdf. Accessed date 14 Nov 2022. Japanese"},{"key":"7805_CR3","doi-asserted-by":"publisher","first-page":"E352","DOI":"10.1503\/cmaj.151276","volume":"188","author":"L Wang","year":"2016","unstructured":"Wang L, Guyatt GH, Kennedy SA, Romerosa B, Kwon HY, Kaushal A, Chang Y, Craigie S, de Almeida CPB, Couban RJ, Parascandalo SR, Izhar Z, Reid S, Khan JS, McGillion M, Busse JW (2016) Predictors of persistent pain after breast cancer surgery: a systematic review and meta-analysis of observational studies. CMAJ 188:E352\u2013E361","journal-title":"CMAJ"},{"key":"7805_CR4","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.jpainsymman.2015.12.340","volume":"51","author":"MH van den Beuken-van Everdingen","year":"2016","unstructured":"van den Beuken-van Everdingen MH, Hochstenbach LM, Joosten EA, Tjan-Heijnen VC, Janssen DJ (2016) Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. J Pain Symptom Manage 51:1070-1090.e1079","journal-title":"J Pain Symptom Manage"},{"key":"7805_CR5","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3322\/caac.21453","volume":"68","author":"BM Scarborough","year":"2018","unstructured":"Scarborough BM, Smith CB (2018) Optimal pain management for patients with cancer in the modern era. CA Cancer J Clin 68:182\u2013196","journal-title":"CA Cancer J Clin"},{"key":"7805_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0304-3959(03)00241-0","volume":"104","author":"BF Jung","year":"2003","unstructured":"Jung BF, Ahrendt GM, Oaklander AL, Dworkin RH (2003) Neuropathic pain following breast cancer surgery: proposed classification and research update. Pain 104:1\u201313","journal-title":"Pain"},{"key":"7805_CR7","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/j.1526-4637.2006.00220.x","volume":"8","author":"AW Burton","year":"2007","unstructured":"Burton AW, Fanciullo GJ, Beasley RD, Fisch MJ (2007) Chronic pain in the cancer survivor: a new frontier. Pain Med 8:189\u2013198","journal-title":"Pain Med"},{"key":"7805_CR8","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.jpainsymman.2012.06.003","volume":"45","author":"K Hofs\u00f8","year":"2013","unstructured":"Hofs\u00f8 K, Rust\u00f8en T, Cooper BA, Bjordal K, Miaskowski C (2013) Changes over time in occurrence, severity, and distress of common symptoms during and after radiation therapy for breast cancer. J Pain Symptom Manage 45:980\u20131006","journal-title":"J Pain Symptom Manage"},{"key":"7805_CR9","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1097\/00000542-200010000-00038","volume":"93","author":"FM Perkins","year":"2000","unstructured":"Perkins FM, Kehlet H (2000) Chronic pain as an outcome of surgery. a review of predictive factors. Anesthesiology 93:1123\u20131133","journal-title":"Anesthesiology"},{"key":"7805_CR10","unstructured":"Ogawa A, Kizawa Y, Yamamoto R, Japan Medical Association (eds) (2019) New edition of cancer palliative care guidebook. Seikaisha, Tokyo. Japanese"},{"key":"7805_CR11","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1093\/annonc\/mdn700","volume":"20","author":"M Costantini","year":"2009","unstructured":"Costantini M, Ripamonti C, Beccaro M, Montella M, Borgia P, Casella C, Miccinesi G (2009) Prevalence, distress, management, and relief of pain during the last 3 months of cancer patients\u2019 life. Results of an Italian mortality follow-back survey. Ann Oncol 20:729\u2013735","journal-title":"Ann Oncol"},{"key":"7805_CR12","first-page":"1","volume":"1","author":"LM Sabik","year":"2022","unstructured":"Sabik LM, Eom KY, Sun Z, Merlin JS, Bulls HW, Moyo P, Pruskowski JA, van Londen GJ, Rosenzweig M, Schenker Y (2022) Patterns and trends in receipt of opioids among patients receiving treatment for cancer in a large health system. J Natl Compr Canc Netw 1:1\u20138","journal-title":"J Natl Compr Canc Netw"},{"key":"7805_CR13","doi-asserted-by":"publisher","unstructured":"Chen Y, Spillane S, Shiels MS, Young L, Quach D, Berrington de Gonz\u00e1lez A, Freedman ND (2022) Trends in opioid use among cancer patients in the United States: 2013\u20132018. JNCI Cancer Spectr 6:pkab095. https:\/\/doi.org\/10.1093\/jncics\/pkab095","DOI":"10.1093\/jncics\/pkab095"},{"key":"7805_CR14","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1097\/NCC.0b013e3182664c95","volume":"36","author":"HS Wu","year":"2013","unstructured":"Wu HS, Natavio T, Davis JE, Yarandi HN (2013) Pain in outpatients treated for breast cancer: prevalence, pharmacological treatment, and impact on quality of life. Cancer Nurs 36:229\u2013235","journal-title":"Cancer Nurs"},{"key":"7805_CR15","unstructured":"Compliance and Narcotics Division, Pharmaceutical Safety and Environmental Health Bureau, Ministry of Health, Labour and Welfare (2017) [Guidance of adequate use in medical narcotics]. https:\/\/www.mhlw.go.jp\/bunya\/iyakuhin\/yakubuturanyou\/other\/iryo_tekisei_guide.html. Accessed date 14 Nov 2022. Japanese"},{"key":"7805_CR16","doi-asserted-by":"publisher","first-page":"197","DOI":"10.5539\/gjhs.v4n6p197","volume":"4","author":"T Higashi","year":"2012","unstructured":"Higashi T, Yoshimoto T, Matoba M (2012) Prevalence of analgesic prescriptions among patients with cancer in Japan: an analysis of health insurance claims data. Glob J Health Sci 4:197\u2013203","journal-title":"Glob J Health Sci"},{"key":"7805_CR17","doi-asserted-by":"crossref","unstructured":"Iwamoto M, Higashi T, Miura H, Kawaguchi T, Tanaka S, Yamashita I, Yoshimoto T, Yoshida S, Matoba M (2015) Accuracy of using diagnosis procedure combination administrative claims data for estimating the amount of opioid consumption among cancer patients in Japan. Jpn J Clin Oncol 45:1036\u20131041","DOI":"10.1093\/jjco\/hyv130"},{"key":"7805_CR18","first-page":"279","volume":"55","author":"M Ishii","year":"2012","unstructured":"Ishii M (2012) DRG\/PPS and DPC\/PDPS as prospective payment systems. Japan Medl Assoc J 55:279\u2013291","journal-title":"Japan Medl Assoc J"},{"key":"7805_CR19","unstructured":"Central Social Insurance Medical Council, Ministry of Health, Labour and Welfare (2021) [499th General Meeting of Central Social Insurance Medical Council, Agenda]. https:\/\/www.mhlw.go.jp\/content\/12404000\/000857756.pdf. Accessed date 26 Apr 2023. Japanese"},{"key":"7805_CR20","unstructured":"World Health Organization (2019) WHO Guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. https:\/\/www.who.int\/publications\/i\/item\/9789241550390. Accessed date 14 Nov 2022"},{"key":"7805_CR21","doi-asserted-by":"publisher","first-page":"e1574","DOI":"10.1634\/theoncologist.2019-0868","volume":"25","author":"C Shen","year":"2020","unstructured":"Shen C, Thornton JD, Gu D, Dodge D, Zhou S, He W, Zhao H, Giordano SH (2020) Prolonged opioid use after surgery for early-stage breast cancer. Oncologist 25:e1574\u2013e1582","journal-title":"Oncologist"},{"key":"7805_CR22","doi-asserted-by":"crossref","unstructured":"Mawatari H, Shinjo T, Morita T, Kohara H, Yomiya K (2022) Revision of pharmacological treatment recommendations for cancer pain: clinical guidelines from the japanese society of palliative medicine. J Palliat Med 25:1095\u20131114","DOI":"10.1089\/jpm.2021.0438"},{"key":"7805_CR23","unstructured":"Japan Society of Pain Clinicians (eds) (2019) Pain clinic treatment policy revision, 6th Edn. Shinko Trading Company Ltd., Tokyo. Japanese"},{"key":"7805_CR24","doi-asserted-by":"publisher","first-page":"326","DOI":"10.2165\/00003495-199141030-00002","volume":"41","author":"PJ Hoskin","year":"1991","unstructured":"Hoskin PJ, Hanks GW (1991) Opioid agonist-antagonist drugs in acute and chronic pain states. Drugs 41:326\u2013344","journal-title":"Drugs"},{"key":"7805_CR25","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.breast.2012.01.019","volume":"21","author":"E Alves NogueiraFabro","year":"2012","unstructured":"Alves NogueiraFabro E, Bergmann A, do Amaral ESB, Padula Ribeiro AC, de Souza Abrah\u00e3o K, da Costa Leite Ferreira MG, de Almeida Dias R, Santos Thuler LC (2012) Post-mastectomy pain syndrome: incidence and risk. S Breast 21:321\u2013325","journal-title":"S Breast"},{"key":"7805_CR26","first-page":"182","volume":"1","author":"HS Smith","year":"2012","unstructured":"Smith HS, Wu SX (2012) Persistent pain after breast cancer treatment. Ann Palliat Med 1:182\u2013194","journal-title":"Ann Palliat Med"},{"key":"7805_CR27","unstructured":"International Narcotics Control Board (2016) Chapter II.Narcotic drugs. In: Availability of internationally controlled drugs: ensuring adequate access for medical and scientific purposes.United Nations, Vienna, pp 23\u221250"},{"key":"7805_CR28","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ejca.2016.10.021","volume":"71","author":"R von Moos","year":"2017","unstructured":"von Moos R, Costa L, Ripamonti CI, Niepel D, Santini D (2017) Improving quality of life in patients with advanced cancer: targeting metastatic bone pain. Eur J Cancer 71:80\u201394","journal-title":"Eur J Cancer"},{"key":"7805_CR29","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jbo.2013.09.001","volume":"2","author":"I Kuchuk","year":"2013","unstructured":"Kuchuk I, Hutton B, Moretto P, Ng T, Addison CL, Clemons M (2013) Incidence, consequences and treatment of bone metastases in breast cancer patients-experience from a single cancer centre. J Bone Oncol 2:137\u2013144","journal-title":"J Bone Oncol"},{"key":"7805_CR30","doi-asserted-by":"publisher","first-page":"21698","DOI":"10.1038\/s41598-020-78569-8","volume":"10","author":"C Shen","year":"2020","unstructured":"Shen C, Thornton JD, Newport K, Schaefer E, Zhou S, Yee NS, Dodge D, Leslie D (2020) Trends and patterns in the use of opioids among metastatic breast cancer patients. Sci Rep 10:21698","journal-title":"Sci Rep"},{"key":"7805_CR31","volume-title":"Guide on estimating requirements for substances under international control","author":"International Narcotics Control Board and the World Health Organization","year":"2012","unstructured":"International Narcotics Control Board and the World Health Organization (2012) Guide on estimating requirements for substances under international control. United Nations, Vienna"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-07805-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-023-07805-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-07805-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T09:10:48Z","timestamp":1686388248000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-023-07805-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["7805"],"URL":"https:\/\/doi.org\/10.1007\/s00520-023-07805-4","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"6 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki and the Ethical Guidelines for Medical and Health Research Involving Human Subjects by the Ministry of Education, Culture, Sports, Science, and Technology and the Ministry of Health, Labor, and Welfare, Japan. Approval was granted by the Ethics Committee of the University of Tokyo (No 31\u201332).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was waived because the collected data were anonymized for secondary use.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Manami Yoshida, Yasuhide Morioka, and Shinzo Hiroi are employees of Shionogi & Co., Ltd., and own shares in Shionogi & Co., Ltd. Kosuke Iwasaki is an employee of Milliman Inc., which has received consulting fees from Shionogi & Co., Ltd. Mitsunori Miyashita has no relevant financial or non-financial interests to disclose. Toshiaki Saeki has received grants from Eisai Co., Ltd., Ono Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., and Taiho Pharmaceutical Co., Ltd., consulting fees from Ono Pharmaceutical Co., Ltd., and honoraria from Eisai Co., Ltd., Ono Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Taiho Pharmaceutical Co., Ltd., Pfizer Japan Inc., Eli Lilly Japan K.K., and Chugai Pharmaceutical Co., Ltd. Eiko Shimizu belongs to the Social Cooperation Program of IT Healthcare, Graduate School of Pharmaceutical Sciences, The University of Tokyo, as a project associate professor sponsored by 10 companies, including Shionogi & Co., Ltd., and has received grants from Shionogi & Co., Ltd., Chugai Pharmaceutical Co., Ltd., Neopharma Japan Co., Ltd., 3H Holdings Inc., Cmic Co., Ltd., AstraZeneca K.K., Mitsubishi Tanabe Pharma Corporation, NTT DATA Corporation, SCSK Corporation, and Aflac Life Insurance Japan Ltd.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"369"}}